Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

GSK uses father-son imagery to promote Oilatum Junior eczema treatment

GlaxoSmithKline (GSK) is using an image of a father and son in an advertising campaign to reflect the “protective” qualities of its Oilatum Junior eczema products.

The image of a “protective” father “draws parallels with Oilatum, which protects a child’s eczema-prone skin from day one”, GSK claimed.

The picture – published in January as part of a wider advertising campaign – will help to inform patients “that Oilatum is gentle enough to use from the very first touch”, the manufacturer added.

As part of the marketing campaign, GSK has also partnered with Amazon and NetDoctor to produce branded articles, videos and social media “focusing on first-time mums”.

The Oilatum Junior range includes a cream and a bath additive, which both contain light liquid paraffin and can treat contact dermatitis, atopic eczema, senile pruritus, ichthyosis and related dry skin conditions, the manufacturer said.

GSK skin health senior brand manager James Sharman said: “At the earliest stages of childhood, skin-to-skin contact is vital for the health and wellbeing of a new-born baby. We hope to bring parent and baby closer than ever with our new visual campaign.”

View the full image:

One 150g tube of Oilatum Junior Cream retails at £5.49 and one 150ml bottle of Oilatum Junior Bath Additive costs £5.09.

To order, contact 0800 783 8881

How often do patients ask you about eczema?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD009250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel